Citius Oncology CTOR
NASDAQ CTOR
$0.76 +0.09 (+13.26%)
As of: Oct 21, 2026 · 9:48 AM EDT

Citius Oncology (CTOR) Gross Margin (2025 - 2026)

Updated

Citius Oncology (CTOR) posted Gross Margin of 67.07% for fiscal Q3 2026 (quarter ended Jun 30, 2026), down 13.20 percentage points from the prior quarter.

Analysis

Citius Oncology (CTOR) Gross Margin (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,139.37 Bn 1,107.95 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 618.39 Bn 536.92 Bn 17.26 Bn 68.19%
3 AbbVie 508.07 Bn 481.19 Bn 12.70 Bn 74.74%
4 Merck 367.07 Bn 321.44 Bn 12.21 Bn 73.54%
5 Novartis Ag 298.65 Bn 262.64 Bn 11.24 Bn 78.02%
6 Astrazeneca 263.08 Bn 236.77 Bn 12.86 Bn 83.60%
7 Amgen 236.65 Bn 192.05 Bn 7.24 Bn 72.04%
8 Gilead Sciences 192.73 Bn 166.92 Bn 6.22 Bn 79.76%
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn 72.78%
10 Citius Oncology 82.00 Mn 51.58 Mn 1.00 Mn 67.07%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 67.07%
Mar 31, 2026 80.27%
Dec 31, 2025 79.99%
API Access

Citius Oncology Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=CTOR&period=max&api_key=YOUR_API_KEY